LPL Financial LLC Has $72.63 Million Stock Position in Gilead Sciences, Inc. (NASDAQ:GILD)

LPL Financial LLC lifted its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 1.9% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 1,058,542 shares of the biopharmaceutical company’s stock after buying an additional 20,186 shares during the quarter. LPL Financial LLC owned about 0.08% of Gilead Sciences worth $72,627,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also modified their holdings of GILD. Gilbert & Cook Inc. lifted its stake in shares of Gilead Sciences by 5.3% in the fourth quarter. Gilbert & Cook Inc. now owns 6,791 shares of the biopharmaceutical company’s stock worth $550,000 after buying an additional 344 shares during the last quarter. Aveo Capital Partners LLC raised its stake in Gilead Sciences by 8.6% during the 4th quarter. Aveo Capital Partners LLC now owns 5,473 shares of the biopharmaceutical company’s stock valued at $443,000 after purchasing an additional 435 shares during the last quarter. Jump Financial LLC raised its stake in Gilead Sciences by 141.2% during the 4th quarter. Jump Financial LLC now owns 7,148 shares of the biopharmaceutical company’s stock valued at $579,000 after purchasing an additional 4,184 shares during the last quarter. Private Wealth Management Group LLC acquired a new position in Gilead Sciences during the 4th quarter valued at $29,000. Finally, NorthRock Partners LLC raised its stake in Gilead Sciences by 50.2% during the 4th quarter. NorthRock Partners LLC now owns 5,732 shares of the biopharmaceutical company’s stock valued at $464,000 after purchasing an additional 1,916 shares during the last quarter. 83.67% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several research firms recently commented on GILD. Truist Financial upped their target price on shares of Gilead Sciences from $82.00 to $83.00 and gave the company a “hold” rating in a research note on Thursday, August 15th. Raymond James upgraded shares of Gilead Sciences from a “market perform” rating to an “outperform” rating and set a $93.00 target price for the company in a research note on Monday, July 8th. Piper Sandler reiterated an “overweight” rating and set a $95.00 target price on shares of Gilead Sciences in a research note on Wednesday. BMO Capital Markets increased their price objective on shares of Gilead Sciences from $80.00 to $85.00 and gave the company an “outperform” rating in a research note on Friday, August 9th. Finally, Royal Bank of Canada increased their price objective on shares of Gilead Sciences from $72.00 to $74.00 and gave the company a “sector perform” rating in a research note on Wednesday, September 4th. Twelve analysts have rated the stock with a hold rating, seven have assigned a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat.com, Gilead Sciences presently has a consensus rating of “Moderate Buy” and an average price target of $82.06.

Gilead Sciences Stock Down 0.4 %

GILD opened at $82.81 on Friday. The firm’s 50-day simple moving average is $75.48 and its 200-day simple moving average is $70.87. The company has a debt-to-equity ratio of 1.18, a quick ratio of 0.95 and a current ratio of 1.14. Gilead Sciences, Inc. has a twelve month low of $62.07 and a twelve month high of $87.86. The firm has a market cap of $103.10 billion, a price-to-earnings ratio of 230.03, a PEG ratio of 2.80 and a beta of 0.18.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Thursday, August 8th. The biopharmaceutical company reported $2.01 EPS for the quarter, topping analysts’ consensus estimates of $1.61 by $0.40. Gilead Sciences had a net margin of 3.79% and a return on equity of 29.34%. The firm had revenue of $6.95 billion for the quarter, compared to analyst estimates of $6.64 billion. Equities research analysts anticipate that Gilead Sciences, Inc. will post 3.78 EPS for the current fiscal year.

Gilead Sciences Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, September 27th. Shareholders of record on Friday, September 13th will be issued a dividend of $0.77 per share. This represents a $3.08 dividend on an annualized basis and a yield of 3.72%. The ex-dividend date is Friday, September 13th. Gilead Sciences’s dividend payout ratio is currently 855.56%.

Insiders Place Their Bets

In other Gilead Sciences news, insider Merdad Parsey sold 2,000 shares of the stock in a transaction dated Monday, July 1st. The shares were sold at an average price of $68.63, for a total transaction of $137,260.00. Following the sale, the insider now owns 96,380 shares of the company’s stock, valued at approximately $6,614,559.40. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In other Gilead Sciences news, insider Merdad Parsey sold 2,000 shares of the company’s stock in a transaction dated Monday, July 1st. The shares were sold at an average price of $68.63, for a total transaction of $137,260.00. Following the transaction, the insider now directly owns 96,380 shares in the company, valued at approximately $6,614,559.40. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Johanna Mercier sold 29,357 shares of the company’s stock in a transaction dated Thursday, September 12th. The shares were sold at an average price of $83.78, for a total transaction of $2,459,529.46. Following the transaction, the insider now owns 78,127 shares in the company, valued at $6,545,480.06. The disclosure for this sale can be found here. Insiders have sold a total of 36,847 shares of company stock valued at $3,002,940 in the last 90 days. 0.16% of the stock is currently owned by insiders.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.